In this research the goal was to produce novel pyrimidine triazole compounds in high yields using triethylamin as an efficient catalyst. These new compounds were synthesized by using multicomponent reaction of aldehydes, guanidine, electron deficient acetylenic compounds, tert-butyl isocyanide and hydrazonoyle chloride in aqueous media. Due to the presence of an NH group, which was assessed using two different methodologies, newly synthesized pyrimidine triazoles have antioxidant properties. Additionally, the antibacterial activity of newly created pyrimidine triazoles was assessed using the disk distribution method with two different types of Gram-positive bacteria and Gram-negative bacteria, demonstrating that the use of these compounds prevented the growth of bacteria. Applied to the preparation of pyrimidine triazole derivatives, this method has short reaction times, high product yields, and the ability to separate catalyst and product using simple procedures.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11030-023-10754-zDOI Listing

Publication Analysis

Top Keywords

pyrimidine triazole
12
preparation pyrimidine
8
triazole derivatives
8
pyrimidine triazoles
8
pyrimidine
5
green preparation
4
derivatives one-pot
4
one-pot multicomponent
4
multicomponent reactions
4
reactions guanidine
4

Similar Publications

Vactosertib, an inhibitor of transforming growth factor β-receptor type-1 (TGFBR1) effective in preventing tumor cell proliferation, is approved for treating various cancers by FDA. The literature revealed that no LC-MS/MS method was reported for the quantification of vactosertib. To develop a validated LC-MS/MS method for the quantification of vactosertib in rat plasma, vactosertib and cabozantinib (internal standard [IS]) were detected using Waters LC-MS/MS system in MRM positive ionization mode, with a mixture of 0.

View Article and Find Full Text PDF

Acquired immunodeficiency syndrome (AIDS) poses a significant threat to life. Antiretroviral therapy is employed to diminish the replication of the human immunodeficiency virus (HIV), extending life expectancy and improving the quality of patients' lives. These HIV-1 integrase inhibitors form robust covalent interactions with Mg ions, contributing to their tight binding, thereby inhibiting the integration of viral DNA into the CD4 cell DNA.

View Article and Find Full Text PDF
Article Synopsis
  • The phosphatidylinositol-3 kinase (PI3K) pathway is crucial in various cancers, making it an attractive target for cancer therapies due to its role in cell survival and metastasis.
  • Mutations or overexpression in PI3K genes (PIK3CA, PIK3CB, PIK3CD, PIK3CG) lead to treatment failures, prompting ongoing clinical trials of PI3K inhibitors to combat drug resistance.
  • Many PI3K inhibitors have faced withdrawal due to safety concerns, but research continues on promising compounds with unique scaffolds to improve therapy efficacy and safety.
View Article and Find Full Text PDF

Recently, due to the widespread use of the acetolactate synthase (ALS)-inhibiting herbicide penoxsulam in paddy fields in China, (L.) P. Beauv.

View Article and Find Full Text PDF

Synergistic potential of lopinavir and azole combinational therapy against clinically important Aspergillus species.

PLoS One

December 2024

Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America.

Aspergillus fumigatus is a widely distributed pathogen responsible for severe infections, particularly in immunocompromised individuals. Triazoles are the primary treatments options for Aspergillus infections; however, the emergence of acquired resistance to this antifungal class is becoming a growing concern. In this study, we investigated the potential of the antiviral drug, lopinavir (LPV) to restore the susceptibility of A.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!